Expert consulting for biotech companies and investors across due diligence, licensing, competitive intelligence, and financial modeling.
Partnership ideation & scoping, target identification, landscape assessment and structured outreach to prospective partners for platform collaborations, asset in-/out-licensing and strategic transactions.
End-to-end support for biopharma licensing and M&A transactions, including comparable deal analysis, deal scoping & structuring, term sheet development and definitive agreement negotiations across therapeutic areas and modalities.
Development of client-bespoke DCF models and customized product/portfolio/scenario analyses (including Monte Carlo simulations) to build valuation frameworks for investment decisions, deal structuring and board-level strategic planning.
Investor targeting, pitch deck development, financial narrative strategy, and process management to support seed, Series A/B and later-stage fundraising for private biotech companies.
Interim and/or part-time CEO, CBO or CFO services for early-stage biotech companies requiring experienced executive leadership without the overhead of a full-time hire.
Expert analysis and testimony for biopharma transaction disputes, including deal valuation, licensing economics, industry-standard practices, and commercial reasonableness (CRE) assessments.